MCL1 and neoplasm: Because of the differential impact of elraglusib on tumor and immune cells that we observed via western blot, we next sought to compare the levels of another survival protein Mcl-1 in NK-92 natural killer cells and we did not observe a significant decrease in Mcl-1 protein expression through the 72-h endpoint (Figure 3B).